Form D · Pharmaceuticals
Ophidion Inc.
Bethlehem, PA · CIK 0001791779
Offering snapshot reported Oct 1, 2024 · SEC filing
- Reported sold
- $655K Offering amount: $1.2M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Sep 17, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 1, 2024 | Initial | $655,166 | No comparison | 8 | SEC filing |
| Sep 7, 2023 | Initial | $1,606,754 | No comparison | 8 | SEC filing |
| Jan 14, 2020 | Amendment | $1,700,000 | $945,000vs Oct 23, 2019 | 12 | SEC filing |
| Oct 23, 2019 | Initial | $755,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-525554
Source: Form D, filed Oct 1, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Claudine Bruck | Director |
| Scott Fishman | Director |
| Yacoub Habib | Director, Executive, Promoter |
| Michael Lark | Director |
| Julie Miwa | Director, Promoter |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
116 Research Dr Suite 223
Bethlehem, PA, 18015
Bethlehem, PA, 18015